As repurposing ivermectin against Covid-19 is still in the focus of debates and as this drug can be formulated with cyclodextrins (see: https://cyclodextrinnews.com/2020/10/09/ivermectin-against-covid-19/), it can be interesting for the followers of Cyclodextrin News that in a randomized open-label trial pilot study the antiviral effects and safety of various doses of ivermectin were assessed in patients with mild clinical symptoms of COVID-19 .
A total of 32 patients were enrolled and randomized to treatment. Standard of care (SOC) treatment together with ivermectin did not result in any serious adverse events. All patients exhibited a reduction in SARS-CoV-2 viral load within 7 days; however, those who received ivermectin had a more consistent decrease as compared to the SOC alone group, characterized by a shorter time for obtaining two consecutive negative SARS-CoV-2 RT PCR tests.
Henrique Pott-Junior, Mônica Maria Bastos Paoliello, Alice de Queiroz Constantino Miguel, Anderson Ferreira da Cunha, Caio Cesar de Melo Freire, Fábio Fernandes Neves, Lucimar Retto da Silva de Avó, Meliza Goi Roscani, Sigrid De Sousa dos Santos, Silvana Gama Florêncio Chachá,
Use of ivermectin in the treatment of Covid-19: A pilot trial,
Toxicology Reports, 8, 2021, 505-510,